伊布替尼治疗慢性淋巴细胞白血病的研究进展  

Research progress of ibrutinib in treatment of chronic lymphoblastic leukemia

作　　者：王茜 陶洁[1] Wang Xi;Tao Jie(Department of Hematology,First Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China)

机构地区：[1]山西医科大学第一医院血液内科,太原030001

出　　处：《国际输血及血液学杂志》2021年第4期350-355,共6页International Journal of Blood Transfusion and Hematology

摘　　要：慢性淋巴细胞白血病(CLL)是常见的成年人白血病。我国CLL发病率虽低,但是呈逐年上升趋势。CLL传统治疗以免疫化疗为主。Bruton酪氨酸激酶(BTK)抑制剂伊布替尼单药应用可显著提高CLL患者的总缓解率(ORR)、无进展生存(PFS)及总体生存(OS)期,但是部分患者存在耐药、复发及难治等情况。为了进一步提高CLL患者的疗效,降低不良反应,并克服耐药,采用伊布替尼联合其他药物治疗CLL的临床试验正在开展,并取得初步成效。笔者拟就伊布替尼单药或者联合用药治疗初治或者复发/难治性CLL患者的研究进展进行综述,以总结2种治疗方案对CLL患者的有效性和安全性。Chronic lymphocytic leukemia(CLL)is a common leukemia in adults.Although morbidity of CLL in China is low,but it increases year by year.Immunochemotherapy is the main therapy for CLL in the past.Application of Bruton tyrosine kinase(BTK)inhibitor ibrutinib significantly improved overall remission rate(ORR),progression-free survival(PFS)and overall survival(OS)time in CLL patients.But some patients were resistant to ibrutinib,relapsed or were refractory.In order to further improve efficacy,overcome drug adverse reactions and resistance,clinical trials of ibrutinib in combination with other drugs to treat CLL are ongoing,and preliminary results were achieved.This article reviews research progress of ibrutinib alone or in combination therapy for primary or recurrent/refractory CLL patients,in order to summarize efficacy and safety of two regimens in treatment of CLL patients.

关 键 词：白血病 淋巴样 蛋白酪氨酸激酶类 复发 药物疗法 联合 伊布替尼 慢性淋巴细胞白血病 

分 类 号：R733.7[医药卫生—肿瘤]